Florian Märkl
YOU?
Author Swipe
View article: Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma
Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma Open
The success of targeted therapies for hematological malignancies has heralded their potential as both salvage treatment and early treatment lines, reducing the need for high-dose, intensive, and often toxic chemotherapeutic regimens. For y…
View article: Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma
Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma Open
In multiple myeloma (MM), B cell maturation antigen (BCMA)-directed CAR T cells have emerged as a novel therapy with potential for long-term disease control. Anti-BCMA CAR T cells with a CD8-based transmembrane (TM) and CD137 (41BB) as int…
View article: Mutation-specific CAR T cells as precision therapy for IGLV3-21<sup>R110</sup>expressing high-risk chronic lymphocytic leukemia
Mutation-specific CAR T cells as precision therapy for IGLV3-21<sup>R110</sup>expressing high-risk chronic lymphocytic leukemia Open
The concept of precision cell therapy targeting tumor-specific mutations is appealing but requires surface-exposed neoepitopes, which is a rarity in cancer. B cell receptors (BCR) of mature lymphoid malignancies are exceptional in that the…
View article: Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma
Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma Open
Background Melanoma is an immune sensitive disease, as demonstrated by the activity of immune check point blockade (ICB), but many patients will either not respond or relapse. More recently, tumor infiltrating lymphocyte (TIL) therapy has …
View article: Impact of the selective A2AR and A2BR dual antagonist AB928/etrumadenant on CAR T cell function
Impact of the selective A2AR and A2BR dual antagonist AB928/etrumadenant on CAR T cell function Open
Background Chimeric antigen receptor (CAR) T cell therapy has been successfully translated to clinical practice for the treatment of B cell malignancies. The suppressive microenvironment of many malignancies is a bottleneck preventing trea…
View article: 10.01 Effective solid tumor therapy through enhanced recruitment and immune suppression shielded T cells
10.01 Effective solid tumor therapy through enhanced recruitment and immune suppression shielded T cells Open
Background CAR T cell therapy remains ineffective in solid tumors. Scarce T cell infiltration and T cell suppression at the tumor site are two notable therapy limitations. T regulatory (Treg) cells are capable of suppressing effective anti…
View article: P06.03 Bispecific antibody-driven synthetic agonistic receptor engineered T cells lead to specific and conditional therapy in melanoma cancer models
P06.03 Bispecific antibody-driven synthetic agonistic receptor engineered T cells lead to specific and conditional therapy in melanoma cancer models Open
Background Immunotherapeutic approaches, including immune checkpoint blockade and adoptive T cell therapy (ACT) in the form of tumor-infiltrating lymphocytes (TIL), have had marked success in the treatment of melanoma. Despite these succes…
View article: P06.06 Enhancing trafficking and resistance to immunosuppression of synthetic agonistic receptor-transduced T cells in solid tumor models
P06.06 Enhancing trafficking and resistance to immunosuppression of synthetic agonistic receptor-transduced T cells in solid tumor models Open
Background Chimeric antigen receptor therapy – although very efficacious in B cell malignancies – is facing many challenges which limit its success in solid tumors, e.g. on-target off-tumor toxicities, antigen heterogeneity, lack of T cell…
View article: 10.03 Interleukin-22 regulates anti-tumor immunity in mouse models of lung and breast carcinoma
10.03 Interleukin-22 regulates anti-tumor immunity in mouse models of lung and breast carcinoma Open
Background High expression of CD155 (poliovirus receptor, PVR) is associated with a poor prognosis of lung adenocarcinoma (LUAD) and triple-negative breast cancer (TNBC) patients. When overexpressed, this molecule inhibits the antitumor fu…
View article: Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors
Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors Open
The combination of directed migration and immunosuppressive shielding enables effective T cell therapy in solid tumors.
View article: P06.01 Bispecific antibody-driven synthetic agonistic receptor – transduced T cells mediate specific and conditional therapy in melanoma cancer models
P06.01 Bispecific antibody-driven synthetic agonistic receptor – transduced T cells mediate specific and conditional therapy in melanoma cancer models Open
Background Immunotherapeutic approaches, including immune checkpoint blockade and adoptive T cell therapy (ACT) in the form of tumor-infiltrating lymphocytes (TILs), have had marked success in the treatment of melanoma. Despite these succe…